S. Zvada

发表

Optimization of 1st-line antituberculosis dosing regimens using a population pharmacokinetic approach: food effects, drug combinations and pharmacological effects

S. Zvada, 2014 .

A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine

S. Dorman, M. Hatherill, P. Denti, 2019, Antimicrobial Agents and Chemotherapy.

Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients

M. Hatherill, P. Denti, S. Charalambous, 2013, Antimicrobial Agents and Chemotherapy.

Moxifloxacin Population Pharmacokinetics in Patients with Pulmonary Tuberculosis and the Effect of Intermittent High-Dose Rifapentine

M. Hatherill, W. Hanekom, P. Denti, 2012, Antimicrobial Agents and Chemotherapy.

Effects of Four Different Meal Types on the Population Pharmacokinetics of Single-Dose Rifapentine in Healthy Male Volunteers

D. Mitchison, J. van der Walt, G. Roscigno, 2010, Antimicrobial Agents and Chemotherapy.

In Vitro and in Silico Identification and Characterization of Thiabendazole as a Mechanism-Based Inhibitor of CYP1A2 and Simulation of Possible Pharmacokinetic Drug-Drug Interactions

C. Masimirembwa, A. Ungell, H. Dolgos, 2009, Drug Metabolism and Disposition.

In Vitro and in Silico Identification and Characterization of Thiabendazole as a Mechanism-Based Inhibitor of CYP1A2 and Simulation of Possible Pharmacokinetic Drug-Drug Interactions

C. Masimirembwa, A. Ungell, H. Dolgos, 2009, Drug Metabolism and Disposition.

IN VITRO AND IN SILICO IDENTIFICATION AND CHARACTERISATION OF THIABENDAZOLE AS A MECHANISM-BASED INHIBITOR OF CYP1A2 AND SIMULATION OF POSSIBLE PHARMACOKINETIC DRUG-DRUG INTERACTIONS

C. Masimirembwa, A. Ungell, H. Dolgos, 2009 .

A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents

B. Stray-Pedersen, S. Rusakaniko, S. Zvada, 2020, BMC Pharmacology and Toxicology.

CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe

C. Masimirembwa, S. Zvada, P. Chonzi, 2015, BMC Pharmacology and Toxicology.

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.

P. Butcher, M. Hatherill, S. Charalambous, 2014, The New England journal of medicine.

Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.

P. Denti, P. Donald, H. McIlleron, 2014, The Journal of antimicrobial chemotherapy.

Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe

S. Rusakaniko, S. Zvada, C. Nhachi, 2021, BMC pharmacology & toxicology.

Does Hepatic Impairment Affect the Exposure of Monoclonal Antibodies?

Qin Sun, S. Zvada, K. Reynolds, 2020, Clinical pharmacology and therapeutics.

Pharmacometrics: Opportunity for Reducing Disease Burden in the Developing World: The Case of Africa

J. Steimer, P. Denti, N. Holford, 2013, CPT: pharmacometrics & systems pharmacology.

Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist.

P. Emmerson, V. Reynolds, K. Mather, 2023, Cell metabolism.

FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients

R. Pazdur, G. Reaman, A. Farrell, 2020, Pediatric blood & cancer.

CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe

C. Masimirembwa, S. Zvada, P. Chonzi, 2015, BMC Pharmacology and Toxicology.

Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis.

S. Dorman, M. Hatherill, P. Denti, 2019 .

PREDICTING POTENTIAL CYP450 ENZYME INHIBITION BASED DRUG-DRUG INTERACTION DURING DRUGS PRESCRIPTION USING A COMPUTER AID

S. Zvada, 2013 .

An Experimental Pharmacokinetic Computer Program to Predict Potential Drug-Drug Interactions

C. Masimirembwa, S. Zvada, Simbarashe Peter Zvada, 2009 .

Arylacetamide deacetylase ( AADAC ) gene polymorphism and HIV infection 3 affect the exposure of Rifapentine : a population pharmacokinetics analysis

S. Dorman, M. Hatherill, P. Denti, 2019 .